Adding rapid molecular testing to the continuum of care could help physicians make treatment decisions more quickly, potentially improving outcomes, particularly for patients with community-acquired pneumonia.
Community-acquired pneumonia (CAP), defined as pneumonia acquired in out-of-hospital settings, is one of the most common infectious diseases with a significant impact on mortality and morbidity worldwide.In this regard, a study conducted by the University of Bergen… + Read more
Rapid molecular testing for hospitalized patients with suspected pneumonia could speed treatment
Adding rapid molecular testing to the continuum of care could help physicians make treatment decisions more quickly, potentially improving outcomes, particularly for patients with community-acquired pneumonia. + read more
Supporting the use of molecular testing to diagnose endometrial cancer
A study has determined that molecular testing is a “more effective” way to diagnose endometrial cancer. + read more
Advantages of using short-acting antibiotics to treat pneumonia
A large Canadian study published in PLoS One, based on more than 400,000 cases of community-acquired pneumonia, or CAP, highlights the importance of shortening the duration of antibiotic treatment to three to five days. + read more
Servier is developing a diagnostic test to detect IDH1 mutations
The pharmaceutical company announced a strategic collaboration with QIAGEN through Molecular Results. + read more
New advances accelerate Alzheimer’s disease risk prognosis
In clinical practice, Alzheimer’s disease is clinically diagnosed using a variety of tools, including cognitive testing and brain imaging, but often when patients develop symptoms, opportunities for optimal intervention diminish. + read more
Genetic technology is making progress in diagnosing blood cancers
Cytogenetic techniques remain critical for the treatment of patients with blood cancers. + read more